cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?

Podobne knjige/članki

• Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
  od: Nardo, Giorgia, et al.
  Izdano: (2021)
• The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
  od: Rachiglio, Anna Maria, et al.
  Izdano: (2019)
• Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
  od: Su, Kang-Yi, et al.
  Izdano: (2018)
• cfDNA changes for monitoring of targeted therapy in a primary EGFR mutation lung adenocarcinoma
  od: He, Qiong, et al.
  Izdano: (2020)
• Mechanisms of resistance to EGFR tyrosine kinase inhibitors
  od: Huang, Lihua, et al.
  Izdano: (2015)